A U.S. Bankruptcy Court has approved Anne Wojcicki’s bid to acquire genetic testing company 23andMe through her nonprofit, TTAM Research Institute, for US$305 million. The acquisition, which follows 23andMe's Chapter 11 bankruptcy filing, will include the company's Personal Genome Service, research operations, and Lemonaid Health subsidiary. The deal faced objections from several states regarding customer data privacy, but many have been resolved, though California, Kentucky, Tennessee, Texas, and Utah remain opposed. TTAM has committed to honoring existing privacy policies and offering customers two years of free Experian identity theft monitoring.
Bid by 23andMe’s former CEO to buy company given greenlight by court
U.S. NewsScienceData BreachData breach23andme23andMe
AI Summary
TL;DR: Key points with love ❤️A U.S. Bankruptcy Court has approved Anne Wojcicki’s bid to acquire genetic testing company 23andMe through her nonprofit, TTAM Research Institute, for US$305 million. The acquisition, which follows 23andMe's Chapter 11 bankruptcy filing, will include the company's Personal Genome Service, research operations, and Lemonaid Health subsidiary. The deal faced objections from several states regarding customer data privacy, but many have been resolved, though California, Kentucky, Tennessee, Texas, and Utah remain opposed. TTAM has committed to honoring existing privacy policies and offering customers two years of free Experian identity theft monitoring.
Trending- 1 Nearly 20 years ago: Anne Wojcicki cofounded 23andMe.
- 2 2021: 23andMe went public.
- 3 2023: Data breach occurred.
- 4 September 2024: All independent directors resigned from 23andMe's board.
- 5 Late March 2025: 23andMe filed for Chapter 11 bankruptcy; Anne Wojcicki resigned as CEO.
- 6 May 2025: Regeneron Pharmaceuticals agreed to buy most of 23andMe’s assets for US$256 million.
- 7 June 2025: Final round of bidding held, won by TTAM Research Institute; 27 states and D.C. filed a lawsuit seeking to block the sale without customer consent.
- 8 Friday (June 27 or 28, 2025): U.S. Bankruptcy Judge Brian C. Walsh approved the sale.
- 9 Monday (July 1, 2025): Anne Wojcicki issued a statement; 23andMe reiterated privacy policies.
- 10 Tuesday (July 2, 2025): Associated Press reached out for further comments.
- 11 Coming weeks: Transaction set to officially close.
- 23andMe will be taken private under TTAM Research Institute ownership.
- Unclear if Anne Wojcicki will return as CEO.
- TTAM will honor existing privacy policies and offer identity theft monitoring to customers.
- Ongoing legal evaluation by California Attorney General's office regarding compliance with genetic privacy law.
What: Anne Wojcicki's nonprofit, TTAM Research Institute, received court approval to acquire 23andMe's assets for US$305 million, following a monthslong bidding war and 23andMe's Chapter 11 bankruptcy filing. The acquisition includes 23andMe's core genetic testing services, research, and its telehealth subsidiary, Lemonaid Health. Privacy concerns from several states were acknowledged but largely resolved, though some states remain opposed.
When: Court approval granted on Friday (June 27 or 28, 2025); statement made Monday (July 1, 2025); transaction set to officially close in the coming weeks; 23andMe filed for Chapter 11 bankruptcy in late March 2025; bidding war concluded last month (June 2025); Regeneron's offer was in May 2025; independent directors resigned in September 2024; 23andMe went public in 2021; 2023 data breach.
Where: San Francisco, U.S. Bankruptcy Court (likely Delaware, where Chapter 11 is often filed, but not explicitly stated in article), California, Kentucky, Tennessee, Texas, Utah.
Why: Anne Wojcicki sought to take 23andMe private due to the company's struggle to find a profitable business model since going public and to operate better outside market pressures. The acquisition also addresses the company's bankruptcy and financial strains. Privacy concerns related to customer genetic information also played a role in the legal proceedings.
How: The acquisition was approved by U.S. Bankruptcy Judge Brian C. Walsh after TTAM Research Institute won a final round of bidding against Regeneron Pharmaceuticals. The deal requires TTAM to comply with 23andMe's privacy policies, allow users to delete data or opt out of research, and offer two years of Experian identity theft monitoring. Customers will be notified via email before the acquisition closes.